Rexahn Pharmaceuticals (RNN) : Anson Funds Management Lp added new position in Rexahn Pharmaceuticals during the most recent quarter end. The investment management firm now holds 9,170,000 shares of Rexahn Pharmaceuticals which is valued at $1,558,900 , the company said in a statement filed on Nov 14, 2016 with the SEC.Rexahn Pharmaceuticals makes up approximately 0.83% of Anson Funds Management Lp’s portfolio.
Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in RNN in the latest quarter, The investment management firm added 23,300 additional shares and now holds a total of 4,927,397 shares of Rexahn Pharmaceuticals which is valued at $837,657.Blackrock Fund Advisors boosted its stake in RNN in the latest quarter, The investment management firm added 4,623 additional shares and now holds a total of 44,166 shares of Rexahn Pharmaceuticals which is valued at $7,022.
Rexahn Pharmaceuticals opened for trading at $0.199 and hit $0.2 on the upside on Monday, eventually ending the session at $0.192, with a gain of 1.05% or 0.002 points. The heightened volatility saw the trading volume jump to 20,00,593 shares. Company has a market cap of $46 M.
Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company dedicated to the discovery development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin a potent inhibitor of the protein kinase Akt-1 which focuses on cancer cell proliferation survival angiogenesis metastasis and drug resistance; RX-3117 a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers including colon lung and pancreatic cancer and Supinoxin (RX-5902) a small molecule that inhibits the phosphorylation of p68 which is expressed in cancer cells but not in normal cells results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.